BACKGROUND: TNF inhibitors have revolutionized the treatment of psoriasis vulgaris as well as psoriatic and rheumatoid arthritis and Crohn disease. Despite our understanding that these agents block TNF, their complex mechanism of action in disease resolution is still unclear. OBJECTIVE: To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment. METHODS: In a clinical trial using etanercept TNF inhibitor to treat psoriasis vulgaris (n = 15), Affymetrix gene arrays were used to analyze gene profiles in lesional skin at multiple time points during drug treatment (baseline and weeks 1, 2, 4, and 12) compared with nonlesional skin. Patients were stratified as responders (n = 11) or nonresponders (n = 4) on the basis of histologic disease resolution. Cluster analysis was used to define gene sets that were modulated with similar magnitude and velocity over time. RESULTS: In responders, 4 clusters of downregulated genes and 3 clusters of upregulated genes were identified. Genes downmodulated most rapidly reflected direct inhibition of myeloid lineage immune genes. Upregulated genes included the stable dendritic cell population genes CD1c and CD207 (langerin). Comparison of responders and nonresponders revealed rapid downmodulation of innate IL-1beta and IL-8 sepsis cascade cytokines in both groups, but only responders downregulated IL-17 pathway genes to baseline levels. CONCLUSION: Although both responders and nonresponders to etanercept inactivated sepsis cascade cytokines, response to etanercept is dependent on inactivation of myeloid dendritic cell genes and inactivation of the T(H)17 immune response.
BACKGROUND:TNF inhibitors have revolutionized the treatment of psoriasis vulgaris as well as psoriatic and rheumatoid arthritis and Crohn disease. Despite our understanding that these agents block TNF, their complex mechanism of action in disease resolution is still unclear. OBJECTIVE: To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment. METHODS: In a clinical trial using etanercept TNF inhibitor to treat psoriasis vulgaris (n = 15), Affymetrix gene arrays were used to analyze gene profiles in lesional skin at multiple time points during drug treatment (baseline and weeks 1, 2, 4, and 12) compared with nonlesional skin. Patients were stratified as responders (n = 11) or nonresponders (n = 4) on the basis of histologic disease resolution. Cluster analysis was used to define gene sets that were modulated with similar magnitude and velocity over time. RESULTS: In responders, 4 clusters of downregulated genes and 3 clusters of upregulated genes were identified. Genes downmodulated most rapidly reflected direct inhibition of myeloid lineage immune genes. Upregulated genes included the stable dendritic cell population genes CD1c and CD207 (langerin). Comparison of responders and nonresponders revealed rapid downmodulation of innate IL-1beta and IL-8sepsis cascade cytokines in both groups, but only responders downregulated IL-17 pathway genes to baseline levels. CONCLUSION: Although both responders and nonresponders to etanercept inactivated sepsis cascade cytokines, response to etanercept is dependent on inactivation of myeloid dendritic cell genes and inactivation of the T(H)17 immune response.
Authors: Rajan P Nair; Andreas Ruether; Philip E Stuart; Stefan Jenisch; Trilokraj Tejasvi; Ravi Hiremagalore; Stefan Schreiber; Dieter Kabelitz; Henry W Lim; John J Voorhees; Enno Christophers; James T Elder; Michael Weichenthal Journal: J Invest Dermatol Date: 2008-01-24 Impact factor: 8.551
Authors: Eiko Toichi; Gisela Torres; Thomas S McCormick; Timothy Chang; Mary Ann Mascelli; Catharine L Kauffman; Nancy Aria; Alice B Gottlieb; Daniel E Everitt; Bart Frederick; Charles E Pendley; Kevin D Cooper Journal: J Immunol Date: 2006-10-01 Impact factor: 5.422
Authors: Asifa S Haider; Michelle A Lowes; Mayte Suárez-Fariñas; Lisa C Zaba; Irma Cardinale; Artemis Khatcherian; Inna Novitskaya; Knut M Wittkowski; James G Krueger Journal: J Immunol Date: 2008-02-01 Impact factor: 5.422
Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich Journal: Lancet Date: 2008-05-17 Impact factor: 79.321
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Ralph M Steinman; James G Krueger; Michelle A Lowes Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Alice B Gottlieb; Kevin D Cooper; Thomas S McCormick; Eiko Toichi; Daniel E Everitt; Bart Frederick; Yaowei Zhu; Charles E Pendley; Martin A Graham; Mary Ann Mascelli Journal: Curr Med Res Opin Date: 2007-05 Impact factor: 2.580
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Narat John Eungdamrong; Leanne M Johnson-Huang; Kristine E Nograles; Traci R White; Katherine C Pierson; Tim Lentini; Mayte Suárez-Fariñas; Michelle A Lowes; James G Krueger Journal: J Allergy Clin Immunol Date: 2010-05-14 Impact factor: 10.793
Authors: Amy C Foulkes; David S Watson; Daniel F Carr; John G Kenny; Timothy Slidel; Richard Parslew; Munir Pirmohamed; Simon Anders; Nick J Reynolds; Christopher E M Griffiths; Richard B Warren; Michael R Barnes Journal: J Invest Dermatol Date: 2018-07-17 Impact factor: 8.551